Who Generates Higher Gross Profit? Ascendis Pharma A/S or Bausch Health Companies Inc.

Pharma Giants' Gross Profit Battle: Ascendis vs. Bausch

__timestamp	Ascendis Pharma A/S	Bausch Health Companies Inc.
Wednesday, January 1, 2014	13983000	6008900000
Thursday, January 1, 2015	8118000	7853800000
Friday, January 1, 2016	4606000	7063000000
Sunday, January 1, 2017	1530000	6176000000
Monday, January 1, 2018	10581000	6029000000
Tuesday, January 1, 2019	13375000	6251000000
Wednesday, January 1, 2020	6953000	5778000000
Friday, January 1, 2021	4255000	6040000000
Saturday, January 1, 2022	39037000	5760000000
Sunday, January 1, 2023	222323000	6198000000
Monday, January 1, 2024	319383000

Igniting the spark of knowledge

A Tale of Two Companies: Gross Profit Showdown

In the competitive world of pharmaceuticals, Ascendis Pharma A/S and Bausch Health Companies Inc. have been vying for dominance in gross profit generation since 2014. While Ascendis Pharma A/S has shown impressive growth, with a staggering 1,500% increase in gross profit from 2014 to 2023, Bausch Health Companies Inc. consistently outpaces its rival, maintaining a gross profit that is approximately 20 times higher on average.

The Decade in Review

From 2014 to 2023, Bausch Health Companies Inc. has demonstrated remarkable stability, with gross profits peaking in 2015. In contrast, Ascendis Pharma A/S experienced a significant surge in 2023, marking its highest gross profit in the decade. This data highlights the dynamic nature of the pharmaceutical industry, where strategic decisions and market conditions can lead to dramatic shifts in financial performance.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025